Palatin Technologies (NYSEMKT: PTN)
Some price data may be temporarily unavailable.
Palatin Technologies Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Palatin Technologies Company Info
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
News & Analysis
Why Palatin Technologies Stock Dropped as Much as 21.5% Today
A high-profile analyst questioned the company's recent FDA approval.
Why AMAG Pharmaceuticals, Inc. Is Falling Today
Investors were hit with a barrage of news today. Here's a look at the key details that investors need to know.
Valuation
Earnings Transcripts
Palatin Technologies (PTN) Q3 2020 Earnings Call Transcript
PTN earnings call for the period ending March 31, 2020.
Palatin Technologies (PTN) Q2 2020 Earnings Call Transcript
PTN earnings call for the period ending December 31, 2019.
Palatin Technologies (PTN) Q1 2020 Earnings Call Transcript
PTN earnings call for the period ending September 30, 2019.
Palatin Technologies (PTN) Q4 2019 Earnings Call Transcript
PTN earnings call for the period ending June 30, 2019.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.